» Articles » PMID: 22791757

Combined Effects of the Variants FSHB -211G>T and FSHR 2039A>G on Male Reproductive Parameters

Overview
Specialty Endocrinology
Date 2012 Jul 14
PMID 22791757
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Context: A polymorphism in the FSHB promoter (-211G>T, rs10835638) was shown to influence male serum FSH levels, whereas a polymorphism in the FSH receptor gene (FSHR; 2039A>G, rs6166) was previously shown to be associated with FSH levels in women only.

Objective: The objective of the study was to analyze the effects of both FSHB -211G>T and FSHR 2039A>G on male reproductive parameters.

Design And Setting: A total of 1213 German men attending an infertility clinic were genotyped by TaqMan assay.

Patients: Patients included male partners in infertile couples without known causes for male infertility.

Main Outcome Measures: An association analysis of single and combined single-nucleotide polymorphism genotypes with clinical parameters was performed.

Results: The FSHB -211G>T T-allele showed significant dosage effects for FSH (-0.51 U/liter per T-allele), LH (0.28 U/liter), and bitesticular volume (-3.2 ml). Statistical significance was enhanced severalfold after a meta-analysis comprising 3017 men. TT carriers were significantly more prevalent among men with lower sperm counts. The FSHR 2039A>G G-allele exhibited nonsignificant trends for associations with higher FSH and reduced testicular volumes. However, in the combined model, FSHR 2039A>G significantly modulated the more dominant effect of FSHB -211G>T on serum FSH and testicular volume among the T-allele carriers.

Conclusions: By analyzing both single-nucleotide polymorphisms for the first time, we convincingly show that indeed FSHR 2039A>G has an effect also in males. In the proposed model of the combined effects, FSHB -211G>T acts strongly on male reproductive parameters, whereas the FSHR 2039A>G effects were approximately 2-3 times smaller. Clinically this is of importance because oligozoospermic patients carrying unfavorable variants affecting FSH action may benefit from FSH treatment.

Citing Articles

Current drawbacks and future perspectives in the diagnosis and treatment of male factor infertility, with a focus on FSH treatment: an expert opinion.

Santi D, Corona G, Salonia A, Ferlin A J Endocrinol Invest. 2025; .

PMID: 39804439 DOI: 10.1007/s40618-024-02524-x.


Deficiency Leads to Morphological and Phenotypic Abnormalities of Spermatocytes and Spermatozoa and Causes Male Infertility.

Cui Y, Zhou M, He Q, He Z Cells. 2023; 12(9).

PMID: 37174664 PMC: 10177581. DOI: 10.3390/cells12091264.


Immune and spermatogenesis-related loci are involved in the development of extreme patterns of male infertility.

Cervan-Martin M, Tuttelmann F, Lopes A, Bossini-Castillo L, Rivera-Egea R, Garrido N Commun Biol. 2022; 5(1):1220.

PMID: 36357561 PMC: 9649734. DOI: 10.1038/s42003-022-04192-0.


The impact of male factors and their correct and early diagnosis in the infertile couple's pathway: 2021 perspectives.

Pallotti F, Barbonetti A, Rastrelli G, Santi D, Corona G, Lombardo F J Endocrinol Invest. 2022; 45(10):1807-1822.

PMID: 35349114 PMC: 8961097. DOI: 10.1007/s40618-022-01778-7.


A GWAS in Idiopathic/Unexplained Infertile Men Detects a Genomic Region Determining Follicle-Stimulating Hormone Levels.

Schubert M, Perez Lanuza L, Woste M, Dugas M, Carmona F, Palomino-Morales R J Clin Endocrinol Metab. 2022; 107(8):2350-2361.

PMID: 35305013 PMC: 9282256. DOI: 10.1210/clinem/dgac165.